SCPX — Scorpius Holdings Share Price
- $0.64m
- $2.92m
- $6.99m
- 16
- 82
- 13
- 30
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.02 | ||
Price to Tang. Book | 0.02 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.06 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -84.75% | ||
Return on Equity | -91.23% | ||
Operating Margin | -305.45% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 3.05 | 2.95 | 2.11 | 0.37 | 6.99 | 8 | 16 | 3.84% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Scorpius Holdings, Inc. is a contract development and manufacturing organization (CDMO) that provides process development and biomanufacturing services to support the biomanufacturing needs of third parties who use its biomanufacturing capacity as a fee-for-service model through its subsidiary, Scorpius Biomanufacturing, Inc. The Company couples Current Good Manufacturing Practices (CGMP) biomanufacturing and quality control knowledge with capabilities in immunoassays, molecular assays, and bioanalytical methods to support cell- and gene-based therapies as well as large molecule biologics using American-made equipment, reagents, and materials. It offers an array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. The Company's CDMO service offerings also include enhanced microbial and mammalian development and manufacturing services.
Directors
- Jeffrey Wolf CHM (57)
- William Ostrander CFO (53)
- John Prendergast LED (67)
- John Monahan IND (74)
- Edward Smith IND (46)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- June 10th, 2008
- Public Since
- July 24th, 2013
- No. of Shareholders
- 31
- No. of Employees
- 82
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NYSE MKT
- Shares in Issue
- 4,868,268

- Address
- 1305 E. Houston Street, Building 2, SAN ANTONIO, 78205
- Web
- https://www.nighthawkbio.com/
- Phone
- +1 9192407133
- Auditors
- BDO USA, P.C.
Upcoming Events for SCPX
Q1 2025 Scorpius Holdings Inc Earnings Release
Scorpius Holdings Inc Annual Shareholders Meeting
Q2 2025 Scorpius Holdings Inc Earnings Release
Similar to SCPX
Can Fite Biopharma
NYSE MKT
cbdMD
NYSE MKT
China Pharma Holdings
NYSE MKT
NovaBay Pharmaceuticals
NYSE MKT
Protalix Biotherapeutics
NYSE MKT
FAQ
As of Today at 23:06 UTC, shares in Scorpius Holdings are trading at $0.13. This share price information is delayed by 15 minutes.
Shares in Scorpius Holdings last closed at $0.13 and the price had moved by -99.59% over the past 365 days. In terms of relative price strength the Scorpius Holdings share price has underperformed the S&P500 Index by -99.61% over the past year.
The overall consensus recommendation for Scorpius Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreScorpius Holdings does not currently pay a dividend.
Scorpius Holdings does not currently pay a dividend.
Scorpius Holdings does not currently pay a dividend.
To buy shares in Scorpius Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.13, shares in Scorpius Holdings had a market capitalisation of $0.64m.
Here are the trading details for Scorpius Holdings:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: SCPX
Based on an overall assessment of its quality, value and momentum Scorpius Holdings is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Scorpius Holdings is $5.00. That is 3687.88% above the last closing price of $0.13.
Analysts covering Scorpius Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$7.26 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scorpius Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -82.16%.
As of the last closing price of $0.13, shares in Scorpius Holdings were trading -88.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Scorpius Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Scorpius Holdings' management team is headed by:
- Jeffrey Wolf - CHM
- William Ostrander - CFO
- John Prendergast - LED
- John Monahan - IND
- Edward Smith - IND